RPRX实时信号 | 通过Getagraph.com最大化利润

出售 81 min ago

@ $28.15

发出时间: 29 Apr 2024 @ 22:40

回报率: -0.52%

上一信号: Apr 27 - 01:00

上一信号: 购买

回报率: 0.25 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 00:01):

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States...

Stats
今日成交量	1.12M
平均成交量	2.81M
市值	12.51B
EPS	$0 ( 2024-02-15 )
下一个收益日期	( $0.960 ) 2024-05-09
Last Dividend	$0.200 ( 2023-11-16 )
Next Dividend	$0 ( N/A )
P/E	11.07
ATR14	$0.240 (0.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Fernandez Henry A	Buy	1 240	Class A Ordinary Shares
2024-03-28	Bassler Bonnie L	Buy	1 240	Class A Ordinary Shares
2024-02-20	Riggs Rory B	Buy	300 000	Class A Ordinary Shares
2024-02-20	Riggs Rory B	Sell	30 000	LP interests in RPI US Partners 2019, LP
2024-01-02	Riggs Rory B	Sell	235 200	Class A Ordinary Shares

INSIDER POWER
-36.03
Last 100 transactions
Buy: 3 308 362 \| Sell: 7 318 226

音量相关性

長: -0.13 (neutral)

短: 0.81 (strong)

Signal:(54) Same movement expected

Royalty Pharma plc 相关性

10 最正相关
INCR	0.957
MYSZ	0.939
SPFI	0.937
BMRA	0.933
WATT	0.931
CUTR	0.93
CSSEP	0.925
BWB	0.919
EVLO	0.918
TIVC	0.918

10 最负相关
ESCA	-0.946
AMTBB	-0.945
BRLI	-0.945
GRIL	-0.944
ARIZ	-0.941
CNGL	-0.94
GBRG	-0.936
EMLD	-0.934
LQDA	-0.934
GANX	-0.931

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Royalty Pharma plc 相关性 - 货币/商品

-0.14
( neutral )

-0.35
( neutral )

0.00
( neutral )

-0.60
( weak negative )

0.41
( neutral )

0.12
( neutral )

Royalty Pharma plc 财务报表

Annual	2023
营收:	$2.35B
毛利润:	$1.79B (76.19 %)
EPS:	$2.54

FY	2023
营收:	$2.35B
毛利润:	$1.79B (76.19 %)
EPS:	$2.54

FY	2022
营收:	$2.24B
毛利润:	$2.23B (99.75 %)
EPS:	$0.0978

FY	2021
营收:	$2.29B
毛利润:	$0.00 (0.00 %)
EPS:	$0.922

Financial Reports:

No articles found.

Royalty Pharma plc Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.190 (N/A)	$0.190 (N/A)	$0.200 (N/A)	$0.200 (N/A)	$0.200 (N/A)	$0.200 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Royalty Pharma plc Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.90 - Increase likely (57.98%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.150	2020-09-14
Last Dividend	$0.200	2023-11-16
Next Dividend	$0	N/A
Payout Date	2023-12-15
Next Payout Date	N/A
# dividends	14	--
Total Paid Out	$2.54	--
Avg. Dividend % Per Year	1.17%	--
Score	4.94	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.90
Div. Directional Score	9.45	--

Next Divdend (Est)
(2024-07-01)

$0.205 Estimate 38.46 %

Dividend Stability

0.77 Good

Dividend Score

4.94

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2020	$0.300	0.67%
2021	$0.680	1.45%
2022	$0.760	1.93%
2023	$0.800	2.03%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.482	1.500	0.360	0.540	[0 - 0.5]
returnOnAssetsTTM	0.0693	1.200	7.69	9.23	[0 - 0.3]
returnOnEquityTTM	0.182	1.500	9.09	10.00	[0.1 - 1]
payoutRatioTTM	0.316	-1.000	6.84	-6.84	[0 - 1]
currentRatioTTM	7.90	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	7.87	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.96	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.375	-1.500	3.76	-5.64	[0 - 0.6]
interestCoverageTTM	7.98	1.000	8.15	8.15	[3 - 30]
operatingCashFlowPerShareTTM	6.70	2.00	7.77	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.964	2.00	9.02	10.00	[0 - 20]
debtEquityRatioTTM	0.940	-1.500	6.24	-9.36	[0 - 2.5]
grossProfitMarginTTM	0.697	1.000	1.719	1.719	[0.2 - 0.8]
operatingProfitMarginTTM	0.634	1.000	10.00	10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.488	1.000	8.40	8.40	[0.2 - 2]
assetTurnoverTTM	0.144	0.800	-2.38	-1.900	[0.5 - 2]
Total Score				11.00

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	11.02	1.000	8.99	0	[1 - 100]
returnOnEquityTTM	0.182	2.50	9.41	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.964	2.00	9.35	10.00	[0 - 30]
dividendYielPercentageTTM	2.89	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.70	2.00	7.77	10.00	[0 - 30]
payoutRatioTTM	0.316	1.500	6.84	-6.84	[0 - 1]
pegRatioTTM	0.802	1.500	7.99	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	1.271	1.000	10.00	0	[0.1 - 0.5]
Total Score				7.90

Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.